{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:24:26Z","timestamp":1791944666902,"version":"4.3.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2022,6,7]]},"abstract":"\n Background<\/jats:title>\n \n In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention\u2013related ischemic complications without increasing major bleeding. This study was performed to examine cangrelor use and transition to oral P2Y\n 12<\/jats:sub>\n inhibitors in routine clinical practice.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n The CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry is a multicenter, retrospective observational study of platelet inhibition strategies for patients with myocardial infarction undergoing percutaneous coronary intervention. In phase 1, data were collected on consecutive patients with myocardial infarction (n=482) treated with any P2Y\n 12<\/jats:sub>\n inhibitor to understand cangrelor use by hospital. In phase 2, data were collected in a 2:1 (cangrelor\u2010: non\u2010cangrelor\u2010treated) ratio of patients with myocardial infarction (n=873). In phase 1, cangrelor use varied across hospitals (overall, 50.4% [range, 6.0%\u2013100%]). Of patients receiving cangrelor in both phases (n=819), 3.3% received either the bolus or infusion only. Cangrelor was infused for a median of 121 (76\u2013196) minutes; and 38.3% received an infusion for <2\u00a0hours. Most patients transitioned from cangrelor to ticagrelor (ticagrelor, 85.3%; clopidogrel, 9.5%; prasugrel, 5.2%). Many patients (16.4%) had a >1\u2010hour gap between cangrelor cessation and oral P2Y\n 12<\/jats:sub>\n inhibitor initiation; this was highest among those transitioned to clopidogrel (56.6% versus 34.5% prasugrel versus 10.8% ticagrelor;\n P<\/jats:italic>\n <0.001). Only 27.3% were dosed with cangrelor and transitioned to an oral P2Y\n 12<\/jats:sub>\n inhibitor in a fashion consistent with the pivotal trials and US Food and Drug Administration label.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n This multicenter registry demonstrated interhospital variability in how cangrelor was administered and transitioned to an oral P2Y\n 12<\/jats:sub>\n inhibitor. These findings highlight opportunities for optimization of cangrelor dosing, infusion duration, and transition of care from the catheterization laboratory to the ward setting.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/jaha.121.024513","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T07:11:46Z","timestamp":1653635506000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Cangrelor Use Patterns and Transition to Oral P2Y\n 12<\/sub>\n Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry"],"prefix":"10.1161","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-2393","authenticated-orcid":false,"given":"Jennifer A.","family":"Rymer","sequence":"first","affiliation":[{"name":"Division of Cardiology Duke University Medical Center Durham NC"},{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine Brigham and Women\u2019s HospitalHarvard Medical School Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-2131","authenticated-orcid":false,"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of Florida Jacksonville FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Diaz","sequence":"additional","affiliation":[{"name":"Palmetto General Hospital Hialeah FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk N.","family":"Garratt","sequence":"additional","affiliation":[{"name":"Division of Cardiology ChristianaCare Wilmington DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9226","authenticated-orcid":false,"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[{"name":"Division of Cardiology MedStar Health Columbia MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Edwards","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudaye","family":"Tasissa","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Salahuddin","sequence":"additional","affiliation":[{"name":"Chiesi USA Cary NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-912X","authenticated-orcid":false,"given":"Hijrah","family":"El\u2010Sabae","sequence":"additional","affiliation":[{"name":"Chiesi USA Cary NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Dell\u2019Anna","sequence":"additional","affiliation":[{"name":"Chiesi USA Cary NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Davidson\u2010Ray","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Washam","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology Duke University Medical Center Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[{"name":"Division of Cardiology Duke University Medical Center Durham NC"},{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology Duke University Medical Center Durham NC"},{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344986"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300815"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61615-3"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022125"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908628"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908629"},{"key":"e_1_3_2_8_2","unstructured":"FDA Labeling for Cangrelor. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204958Orig1s000Lbl.pdf. Accessed May 10 2021."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031164"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.08.004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.828541"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.10.004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.16.1912"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.24.3108"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240903"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.08.017"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000158"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.07.009"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.121.024513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:51:26Z","timestamp":1715586686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.121.024513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,7]]}},"alternative-id":["10.1161\/JAHA.121.024513"],"URL":"https:\/\/doi.org\/10.1161\/jaha.121.024513","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"2021-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e024513"}}